dTIP is an ETH technology platform created to support researchers in clinical evidence generation and support entrepreneurs with the regulatory aspects of product development. dTIP is built around three interdisciplinary expert units, staffed with clinical trials, data management and regulatory experts. We collaborate with clinical and non-clinical partners within academia and/or industry in order to deliver a high quality service for clinical trials and along the product development life cycle.
Our vision is to generate human evidence for new medical solutions at ETH Zurich.
Kantonsspital Baden (KSB) has developed a groundbreaking vacuum-based retention device to facilitate kidney surgeries. Surgeons at KSB, in collaboration with researchers from ETH, are now planning a two-phase study to validate the added value in terms of safety and benefits of their patented invention.
At dTIP, we are proud to be a key partner in the RAPID trial, a ground-breaking initiative funded by PHRT to evaluate an ex-vivo drug testing platform developed by Snijder Lab, ETH Zurich. This trial approach, which aims to proof a (r)evolutionary treatment of acute myeloid leukaemia, has benefited from dTIP's extensive expertise.
Researchers at ETH Zurich have studied topological effects in an artificial solid, making surprising observations. The new insights into topological pumping could be used for quantum technologies in the future.
In its annual report 2023 published today, ETH Zurich looks back on a successful year. For some years, however, the budget has not kept pace with the growth in student numbers. The growth rates projected by the Federal Council in the 2025-2028 ERI Dispatch are therefore forcing the university to consider drastic measures in research and teaching.
On behalf of Raiffeisen Switzerland Cooperative, ETH Zurich researchers examined the beginnings of the Raiffeisen movement in Switzerland. Their focus was on antisemitism as well as Raiffeisen during National Socialism.
